SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more ...
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback